David Gallego-Ortega
David Gallego-Ortega
Associate Professor University of Technology Sydney & Garvan Institute of Medical Research
Verified email at uts.edu.au
Title
Cited by
Cited by
Year
Expression of choline kinase alpha to predict outcome in patients with early-stage non-small-cell lung cancer: a retrospective study
AR de Molina, J Sarmentero-Estrada, C Belda-Iniesta, M Tarón, ...
The lancet oncology 8 (10), 889-897, 2007
1672007
Transient tissue priming via ROCK inhibition uncouples pancreatic cancer progression, sensitivity to chemotherapy, and metastasis
C Vennin, VT Chin, SC Warren, MC Lucas, D Herrmann, A Magenau, ...
Science translational medicine 9 (384), 2017
1662017
Myeloid-derived suppressor cells as a therapeutic target for cancer
AMK Law, F Valdes-Mora, D Gallego-Ortega
Cells 9 (3), 561, 2020
1082020
Differential role of human choline kinase α and β enzymes in lipid metabolism: implications in cancer onset and treatment
D Gallego-Ortega, A Ramirez de Molina, MA Ramos, F Valdes-Mora, ...
PloS one 4 (11), e7819, 2009
1072009
Choline kinase as a link connecting phospholipid metabolism and cell cycle regulation: implications in cancer therapy
AR de Molina, D Gallego-Ortega, J Sarmentero-Estrada, D Lagares, ...
The international journal of biochemistry & cell biology 40 (9), 1753-1763, 2008
982008
TWIST1 overexpression is associated with nodal invasion and male sex in primary colorectal cancer
F Valdes-Mora, TG Del Pulgar, E Bandres, P Cejas, AR De Molina, ...
Annals of surgical oncology 16 (1), 78-87, 2009
932009
Choline kinase is a novel oncogene that potentiates RhoA-induced carcinogenesis
AR de Molina, D Gallego-Ortega, J Sarmentero, M Bañez-Coronel, ...
Cancer research 65 (13), 5647-5653, 2005
932005
Progesterone drives mammary secretory differentiation via RankL-mediated induction of Elf5 in luminal progenitor cells
HJ Lee, D Gallego-Ortega, A Ledger, D Schramek, P Joshi, MM Szwarc, ...
Development 140 (7), 1397-1401, 2013
922013
ELF5 suppresses estrogen sensitivity and underpins the acquisition of antiestrogen resistance in luminal breast cancer
M Kalyuga, D Gallego-Ortega, HJ Lee, DL Roden, MJ Cowley, CE Caldon, ...
PLoS biology 10 (12), e1001461, 2012
852012
Regulation of Akt (ser473) phosphorylation by choline kinase in breast carcinoma cells
BT Chua, D Gallego-Ortega, AR De Molina, A Ullrich, JC Lacal, ...
Molecular Cancer 8 (1), 1-12, 2009
762009
The innate and adaptive infiltrating immune systems as targets for breast cancer immunotherapy
AMK Law, E Lim, CJ Ormandy, D Gallego-Ortega
Endocrine-related cancer 24 (4), R123, 2017
742017
Involvement of Lyn and the atypical kinase SgK269/PEAK1 in a basal breast cancer signaling pathway
DR Croucher, F Hochgräfe, L Zhang, L Liu, RJ Lyons, D Rickwood, ...
Cancer research 73 (6), 1969-1980, 2013
732013
A RhoA-FRET biosensor mouse for intravital imaging in normal tissue homeostasis and disease contexts
M Nobis, D Herrmann, SC Warren, S Kadir, W Leung, M Killen, ...
Cell reports 21 (1), 274-288, 2017
692017
The mammary cellular hierarchy and breast cancer
SR Oakes, D Gallego-Ortega, CJ Ormandy
Cellular and Molecular Life Sciences 71 (22), 4301-4324, 2014
622014
Involvement of human choline kinase alpha and beta in carcinogenesis: a different role in lipid metabolism and biological functions.
D Gallego-Ortega, T Gómez del Pulgar, F Valdés-Mora, A Cebrián, ...
Advances in enzyme regulation 51 (1), 183-194, 2010
612010
ELF5 drives lung metastasis in luminal breast cancer through recruitment of Gr1+ CD11b+ myeloid-derived suppressor cells
D Gallego-Ortega, A Ledger, DL Roden, AMK Law, A Magenau, ...
PLoS biology 13 (12), e1002330, 2015
542015
Acetylated histone variant H2A. Z is involved in the activation of neo-enhancers in prostate cancer
F Valdés-Mora, CM Gould, Y Colino-Sanguino, W Qu, JZ Song, KM Taylor, ...
Nature communications 8 (1), 1-17, 2017
532017
Lineage Specific Methylation of the Elf5 Promoter in Mammary Epithelial Cells
HJ Lee, RA Hinshelwood, T Bouras, D Gallego‐Ortega, F Valdés‐Mora, ...
Stem cells 29 (10), 1611-1619, 2011
512011
MCL-1 inhibition provides a new way to suppress breast cancer metastasis and increase sensitivity to dasatinib
AIJ Young, AMK Law, L Castillo, S Chong, HD Cullen, M Koehler, ...
Breast Cancer Research 18 (1), 1-15, 2016
502016
BCL-2 hypermethylation is a potential biomarker of sensitivity to antimitotic chemotherapy in endocrine-resistant breast cancer
A Stone, MJ Cowley, F Valdes-Mora, RA McCloy, CM Sergio, ...
Molecular cancer therapeutics 12 (9), 1874-1885, 2013
502013
The system can't perform the operation now. Try again later.
Articles 1–20